We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Centerpulse to Sell Heart Valve Business

By HospiMedica staff writers
Posted on 10 Dec 2002
Print article
In a further move to divest its cardiovascular interests, Centerpulse Ltd. (Zurich, Switzerland) has agreed to sell its mechanical and tissue heart valve business to Snia S.p.A. (Milan, Italy) for US$116 million. This business comprises Carbomedics (Austin, TX, USA) and Mitroflow (Vancouver, Canada).

Carbomedics manufactures and markets mechanical and tissue heart valves and heart valve repair products. Since its founding in 1969, nearly 500,000 Carbomedics heart valves have been implanted in human hearts with no single event of postoperative failure, says the company.

Snia is a global manufacturer and distributor of medical devices for cardiopulmonary, surgical blood recovery, heart valve, stent, pacemaker, and defibrillator markets. The acquisition is projected to increase the company's global sales of medical devices to more than US$750 million per year.

Centerpulse notes this is the third and final step in its plan to divest its cardiovascular interests. Earlier this year, the company sold its vascular businesses, Vascutek Ltd. and IntraTherapeutics, Inc. Centerpulse is refining its strategic focus to emphasize the core sectors of orthopedic, spine, and dental implants.




Related Links:
Centerpulse
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
Surgeon Stool with Armrests & Backrest
MR4502
New
Facet Fixation System
ZYFUSE

Print article

Channels

Surgical Techniques

view channel
Image: Graphical abstract; Surgical field during endomyocardial biopsy and fluoroscopic images (Photo courtesy of Heart Rhythm, DOI: 10.1016/j.hrthm.2024.10.069)

Novel Method Combining Heart Biopsy and Device Implantation Reduces Complications Risk

Endomyocardial biopsy (EMB) is a crucial diagnostic tool for identifying various cardiac conditions; however, it carries a risk of complications due to its invasive nature. New research has introduced... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.